# BSX — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-08-05. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 6.7 · Fundamentals 7.8 · Technicals 6.2 · Growth 7 · Risk 6

## Summary

Boston Scientific remains a broken compounder trading at $49 vs. a 52-week high of $109.50, down 48% YTD despite still-robust operating fundamentals (Q1'26 revenue $5.2B, 69.4% gross margin, 25.8% net margin). The stock has stabilized off the $42.20 low, RSI is now 67.6 and above SMA20/50, with insider buying and a modest price-target cut being the fresh signals. Forward P/E of 14.3x on $3.44 forward EPS is reasonable for a mid-teens grower, but prior base targets have consistently overshot the tape — I'm keeping an accumulate stance with disciplined, closer-in targets.

## Price targets (12-month horizon)

- Bear: $42.00
- Base: $57.00
- Bull: $68.00

## News context

The dominant catalyst was the 7/29 Q2 print: revenue $5.44B (+7.5% Y/Y, beat), non-GAAP EPS $0.86 (+3.8% beat), but next-quarter guide $5.27B came in 2.2% light on continued WATCHMAN and EP softness. That drove the 7/30 average price target cut from $70.31 to $62.96 (-10.4%) — a legitimate but not thesis-breaking downgrade to expectations. Separately, one healthcare-focused piece framing an analyst's 35% upside case on Abbott implicitly benchmarks large-cap medtech comps positively. A tangible bullish signal: director Edward Ludwig bought $227k of open-market stock on 7/31, right after the print — insider buying into a guide-down is a conviction signal, though the size is modest. Everything else (StockStory profitability screens, S&P500 gap lists) is context noise.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/bsx-ai-stock-forecast-79b9853f3eaef8d7a02e26ebb71b56dc
- AI-generated; model outputs can be wrong. Not financial advice.